Veradermics (MANE) holder SR One sells 321,749 shares, cuts stake to 4.9%

Rhea-AI Filing Summary

Veradermics, Inc. shareholder SR One–affiliated funds amended their beneficial ownership report after selling shares in a private transaction. On August 12, 2026, SR One Capital Fund II Aggregator and AMZL sold an aggregate of 321,749 Veradermics common shares at $104.30 per share, for total consideration of approximately $33,558,420. After the sale, SR One Capital Fund II Aggregator holds 1,403,959 shares and AMZL holds 676,160 shares, for a combined total of 2,080,119 shares, representing 4.9% of Veradermics’ common stock outstanding based on 41,780,136 shares reported as of August 6, 2026. The reporting persons state they have no current plans regarding control-related actions involving Veradermics but note the funds may dispose of additional shares depending on market conditions. As of August 12, 2026, each reporting person has ceased to beneficially own 5% or more of the issuer’s common stock.

Key Figures

Shares sold: 321,749 shares Sale price per share: $104.30 per share Aggregate sale proceeds: $33,558,420 +5 more

8 metrics

Shares sold 321,749 shares Aggregate Veradermics common shares sold on August 12, 2026 in a privately negotiated transaction

Sale price per share $104.30 per share Price received by SR One Capital Fund II Aggregator and AMZL for Veradermics shares sold

Aggregate sale proceeds $33,558,420 Approximate total consideration from the August 12, 2026 sale of 321,749 shares

Post-sale holdings – Fund II Aggregator 1,403,959 shares Veradermics common shares held by SR One Capital Fund II Aggregator after the transaction

Post-sale holdings – AMZL 676,160 shares Veradermics common shares held by AMZL after the transaction

Total SR One–affiliated holdings 2,080,119 shares Combined Veradermics holdings of SR One Capital Fund II Aggregator and AMZL after the sale

Ownership percentage 4.9% Percentage of Veradermics common stock beneficially owned, based on 41,780,136 shares outstanding

Shares outstanding baseline 41,780,136 shares Veradermics common shares outstanding as of August 6, 2026, used to calculate ownership percentages

Key Terms

beneficially own, dispositive power, privately negotiated transaction, Reporting Person, +1 more

5 terms

beneficially own financial

"each of the Reporting Persons has ceased to beneficially own 5% or more of the Common Stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

dispositive power financial

"shared Dispositive Power 2,080,119.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

privately negotiated transaction financial

"sold an aggregate of 321,749 shares ... in a privately negotiated transaction"

A privately negotiated transaction is a deal whose terms are worked out directly between a buyer and a seller rather than through a public market or open auction. Think of it like selling a car to a neighbor instead of putting it on eBay: the price, timing and conditions are agreed one-on-one, so investors may see less public information, different pricing compared with market trades, and potential impacts on liquidity and valuation.

Reporting Person regulatory

"The persons named in this Item 2 are referred to individually herein as a "Reporting Person""

Schedule 13D regulatory

"previously filed a statement on Schedule 13D to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

FAQ

What stake does SR One now hold in Veradermics (MANE) after this Schedule 13D/A?

Following the reported sale, SR One–affiliated funds collectively hold 2,080,119 Veradermics shares, representing 4.9% of the company’s common stock, based on 41,780,136 shares outstanding as of August 6, 2026.

How many Veradermics (MANE) shares did SR One sell and at what price?

On August 12, 2026, SR One Capital Fund II Aggregator and AMZL sold an aggregate of 321,749 Veradermics common shares in a privately negotiated transaction at $104.30 per share, for total consideration of approximately $33,558,420.

What are the post-transaction holdings of each SR One fund in Veradermics (MANE)?

After the sale, SR One Capital Fund II Aggregator holds 1,403,959 Veradermics shares and AMZL holds 676,160 shares. These positions together total 2,080,119 shares of Veradermics common stock.

When did SR One’s ownership in Veradermics (MANE) fall below 5%?

As of August 12, 2026, each reporting person states they have ceased to beneficially own 5% or more of Veradermics’ common stock, following the privately negotiated sale described in the amended filing.

Does SR One indicate any plans to influence control of Veradermics (MANE)?

The reporting persons state they have no present plans regarding mergers, board changes, capitalization changes, or other control-related actions for Veradermics, though the funds may dispose of additional shares depending on market conditions and other factors.

How is beneficial ownership of Veradermics (MANE) shares structured among the SR One entities?

SR One Capital Fund II Aggregator and AMZL are the record owners. General partners and SR One Capital Management, controlled by Simeon George, M.D., may be deemed to share voting and dispositive power over these holdings, while each party disclaims beneficial ownership beyond shares held of record.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 08:01 PM Accepted by SEC EDGAR 08/14/2026 - 08:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Veradermics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

922967104

(CUSIP Number)

Sasha Keough
c/o SR One Capital Management, LP, 929 Main Street, Suite 200
Redwood City, CA, 94063
(410) 800-7503

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

SR One Capital Management, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,080,119.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,080,119.00

11

Aggregate amount beneficially owned by each reporting person

2,080,119.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.9 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

SR One Capital Fund II Aggregator, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,403,959.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,403,959.00

11

Aggregate amount beneficially owned by each reporting person

1,403,959.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

SR One Capital Partners II, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,403,959.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,403,959.00

11

Aggregate amount beneficially owned by each reporting person

1,403,959.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

AMZL, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 676,160.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 676,160.00

11

Aggregate amount beneficially owned by each reporting person

676,160.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

SR One Capital SMA Partners, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 676,160.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 676,160.00

11

Aggregate amount beneficially owned by each reporting person

676,160.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

Simeon George

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,080,119.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,080,119.00

11

Aggregate amount beneficially owned by each reporting person

2,080,119.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.9 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.00001 par value per share
(b)	Name of Issuer: Veradermics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 470 James Street, New Haven, CONNECTICUT , 06513.
Item 1 Comment: This Amendment No. 1 ("Amendment No. 1") to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on February 11, 2026 (the "Schedule 13D") relating to the Common Stock of the Issuer. Certain terms used but not defined in this Amendment No. 1 have the meaning assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.
Item 2.	Identity and Background
(a)	SR One Capital Management, LLC ("SR One Capital Management"); SR One Capital Fund II Aggregator, LP ("SR One Fund II Aggregator"); SR One Capital Partners II, LP ("SR One Partners II"); AMZL, LP ("AMZL"); SR One Capital SMA Partners, LP ("SMA Partners"); and Simeon George, M.D. ("Dr. George"). SR One Fund II Aggregator is directly controlled by its general partner, SR One Partners II. AMZL is directly controlled by its general partner, SMA Partners. SR One Partners II and SMA Partners are directly controlled by their general partners, SR One Capital Management, and Dr. George controls SR One Capital Management. Accordingly, each of SR One Capital Management and Dr. George may be deemed to have voting and dispositive power with respect to the SR One Fund II Aggregator Shares and the AMZL Shares (each as defined below). The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons." SR One Fund II Aggregator and AMZL are referred to collectively as the "Funds."
(b)	The address of each Reporting Person for purposes of this filing is c/o SR One Capital Management, LP, 929 Main Street, Suite 200, Redwood City, CA 94063.
(c)	The principal business of the Funds is to invest in and assist growth-oriented businesses. The principal business of SR One Partners II is to act as the sole general partner of SR One Fund II Aggregator. The principal business of SMA Partners is to act as the general partner of AMZL. The principal business of SR One Capital Management is to act as the sole general partner of SR One Partners II, SMA Partners and a number of affiliated partnerships with similar businesses. The principal business of Dr. George is to manage SR One Capital Management.
(d)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(e)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	SR One Fund II Aggregator, SR One Partners II, AMZL, and SMA Partners are limited partnerships organized under the laws of the State of Delaware. SR One Capital Management is a limited liability company organized under the laws of the State of Delaware. Dr. George is a United States citizen.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	On August 12, 2026, SR One Fund II Aggregator and AMZL sold an aggregate of 321,749 shares of the Common Stock of the Issuer in a privately negotiated transaction (the "Sale"). In the Sale, SR One Fund II Aggregator sold 217,162 shares of Common Stock and AMZL sold 104,587 shares of Common Stock, in each case at a price of $104.30 per share, for aggregate consideration of approximately $33,558,420. Following the Sale, SR One Fund II Aggregator now holds 1,403,959 shares of Common Stock (the "SR One Fund II Aggregator Shares"), and AMZL now holds 676,160 shares of Common Stock (the "AMZL Shares"). Collectively, the Funds now hold a total of 2,080,119 shares of Common Stock of the Issuer (the "Fund Shares"). Depending on market conditions and other factors, the Funds may dispose of additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.
Item 5.	Interest in Securities of the Issuer
(a)	SR One Fund II Aggregator is the record owner of the SR One Fund II Aggregator Shares. As the general partner of SR One Fund II Aggregator, SR One Partners II may be deemed to beneficially own the SR One Fund II Aggregator Shares. As the general partner of SR One Partners II, SR One Capital Management may be deemed to beneficially own the SR One Fund II Aggregator Shares. As the managing member of SR One Capital Management, Dr. George may be deemed to beneficially own the SR One Fund II Aggregator Shares. AMZL is the record owner of the AMZL Shares. As the general partner of AMZL, SMA Partners may be deemed to beneficially own the AMZL Shares. As the general partner of SMA Partners, SR One Capital Management may be deemed to beneficially own the AMZL Shares. As the managing member of SR One Capital Management, Dr. George may be deemed to beneficially own the AMZL Shares. Each Reporting Person disclaims beneficial ownership of the Fund Shares other than those shares which such person owns of record. The percentage of outstanding shares of Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 41,780,136 shares of Common Stock reported by the Issuer to be outstanding as of August 6, 2026 as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2026.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets
(c)	Except as set forth in Item 4 above, none of the Reporting Persons has effected any transaction in shares of Common Stock during the last 60 days.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.
(e)	As of August 12, 2026, each of the Reporting Persons has ceased to beneficially own 5% or more of the Common Stock of the Issuer.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SR One Capital Management, LLC

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	08/14/2026

SR One Capital Fund II Aggregator, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	08/14/2026

SR One Capital Partners II, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	08/14/2026

AMZL, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	08/14/2026

SR One Capital SMA Partners, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	08/14/2026

Simeon George

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D.
Date:	08/14/2026

Comments accompanying signature:

This Statement was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.